Signal Genetics, Inc. is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company's diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test. The MyPRS test is a microarray-based gene expression profile (GEP), assay that measures the expression level of specific genes and groups of genes that are designed to predict an individual's long-term clinical outcome/prognosis, giving a basis for personalized treatment options. The Company's MyPRS test provides a whole-genomic expression profile of a patient's multiple myeloma (MM). The Company offers MyPRS test in its laboratory located in Little Rock, Arkansas. The Company is licensed to sell its test in all 50 states.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Laboratories & Research
- Sub-Industry: N/A
- Symbol: NASDAQ:MGEN
- CUSIP: N/A
- Web: www.signalgenetics.com
Capitalization:- Market Cap: $313.1 million
- Outstanding Shares: 21,407,000
Average Prices:- 50 Day Moving Avg: $11.72
- 200 Day Moving Avg: $11.82
- 52 Week Range: $1.80 - $18.00
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.97
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $3.02 million
- Price / Sales: 103.70
- Book Value: $2.24 per share
- Price / Book: 6.53
Profitability:- EBIDTA: ($20,050,000.00)
- Net Margins: -555.68%
- Return on Equity: -109.13%
- Return on Assets: -81.59%
Debt:- Debt-to-Equity Ratio: 0.05%
- Current Ratio: 7.83%
- Quick Ratio: 7.83%
Misc:- Average Volume: 61,424 shs.
- Beta: 1.88
- Short Ratio: 5.26
Frequently Asked Questions for Signal Genetics (NASDAQ:MGEN)
What is Signal Genetics' stock symbol?
Signal Genetics trades on the NASDAQ under the ticker symbol "MGEN."
How were Signal Genetics' earnings last quarter?
Signal Genetics, Inc. (NASDAQ:MGEN) issued its earnings results on Wednesday, May, 10th. The company reported ($0.60) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.24) by $0.36. The company earned $0.46 million during the quarter, compared to analyst estimates of $1 million. Signal Genetics had a negative return on equity of 109.13% and a negative net margin of 555.68%. View Signal Genetics' Earnings History.
Where is Signal Genetics' stock going? Where will Signal Genetics' stock price be in 2017?
3 equities research analysts have issued 1-year price targets for Signal Genetics' shares. Their predictions range from $4.00 to $17.00. On average, they anticipate Signal Genetics' stock price to reach $10.50 in the next year. View Analyst Ratings for Signal Genetics.
Who are some of Signal Genetics' key competitors?
Some companies that are related to Signal Genetics include MacroGenics (MGNX), Intellia Therapeutics (NTLA), AnaptysBio (ANAB), AngioDynamics (ANGO), NantKwest (NK), Mesoblast Limited (MESO), Audentes Therapeutics (BOLD), Alder BioPharmaceuticals (ALDR), REGENXBIO (RGNX), Otonomy (OTIC), Seres Therapeutics (MCRB), Achillion Pharmaceuticals (ACHN), GenMark Diagnostics (GNMK), ANI Pharmaceuticals (ANIP), ImmunoGen (IMGN), SciClone Pharmaceuticals (SCLN), Calithera Biosciences (CALA) and AxoGen (AXGN).
How do I buy Signal Genetics stock?
Shares of Signal Genetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Signal Genetics' stock price today?
One share of Signal Genetics stock can currently be purchased for approximately $14.63.
MarketBeat Community Rating for Signal Genetics (NASDAQ MGEN)MarketBeat's community ratings are surveys of what our community members think about Signal Genetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Signal Genetics (NASDAQ:MGEN)Earnings History by Quarter for Signal Genetics (NASDAQ MGEN)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/10/2017 | Q1 2017 | ($0.24) | ($0.60) | $1.00 million | $0.46 million | View | N/A |  |
| 5/16/2016 | Q116 | ($0.28) | ($0.26) | $645.00 million | $808.00 million | View | N/A | |
| 3/16/2016 | Q415 | ($0.36) | ($0.28) | $0.60 million | $0.66 million | View | N/A | |
| 8/12/2015 | Q215 | ($0.39) | ($0.33) | | $0.73 million | View | N/A | |
| 5/14/2015 | Q115 | ($0.36) | ($0.45) | $1.90 million | $0.65 million | View | N/A | |
| 3/30/2015 | | ($0.39) | ($1.72) | | | View | N/A | |
| 11/14/2014 | Q3 2014 | ($0.05) | ($0.43) | | $1.30 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Signal Genetics (NASDAQ:MGEN)2017 EPS Consensus Estimate: ($1.16)
2018 EPS Consensus Estimate: ($1.44)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.24) | ($0.24) | ($0.24) |
| Q2 2017 | 1 | ($0.29) | ($0.29) | ($0.29) |
| Q3 2017 | 1 | ($0.31) | ($0.31) | ($0.31) |
| Q4 2017 | 1 | ($0.32) | ($0.32) | ($0.32) |
| Q1 2018 | 1 | ($0.34) | ($0.34) | ($0.34) |
| Q2 2018 | 1 | ($0.35) | ($0.35) | ($0.35) |
| Q3 2018 | 1 | ($0.37) | ($0.37) | ($0.37) |
| Q4 2018 | 1 | ($0.38) | ($0.38) | ($0.38) |
(Data provided by Zacks Investment Research)
Dividend History for Signal Genetics (NASDAQ:MGEN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Signal Genetics (NASDAQ:MGEN)Insider Ownership Percentage: 44.40%
Institutional Ownership Percentage: 16.35%
Insider Trades by Quarter for Signal Genetics (NASDAQ:MGEN)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/22/2017 | Adam Scott Levy | Insider | Buy | 200 | $7.55 | $1,510.00 | |
| 3/10/2017 | Kyle Lefkoff | Director | Sell | 5,800 | $14.34 | $83,172.00 | |
| 3/8/2017 | Kyle Lefkoff | Director | Sell | 15,000 | $15.40 | $231,000.00 | |
| 2/28/2017 | Kyle Lefkoff | Director | Sell | 10,258 | $13.89 | $142,483.62 | |
| 2/23/2017 | Kyle Lefkoff | Director | Sell | 5,902 | $14.14 | $83,454.28 | |
| 11/20/2015 | Samuel D. Riccitelli | CEO | Buy | 14,000 | $0.79 | $11,060.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Signal Genetics (NASDAQ:MGEN)
Latest Headlines for Signal Genetics (NASDAQ:MGEN)
| Source: |
|
| Date | Headline |
|---|
 | miRagen Therapeutics, Inc. (Nasdaq: MGEN) to Ring The Nasdaq Stock Market Closing Bell
finance.yahoo.com - July 22 at 6:26 AM |
 | Comparing BG Medicine (BGMD) and Signal Genetics (MGEN)
www.americanbankingnews.com - July 21 at 2:26 PM |
| BG Medicine (BGMD) versus Signal Genetics (MGEN) Head-To-Head Review
www.americanbankingnews.com - July 21 at 2:24 PM |
| Zacks Investment Research Upgrades Signal Genetics, Inc. (NASDAQ:MGEN) to "Hold"
www.americanbankingnews.com - July 12 at 7:54 AM |
| Signal Genetics, Inc. (MGEN) Given $26.37 Average Target Price by Brokerages
www.americanbankingnews.com - June 27 at 10:56 AM |
| Should You Get Rid of Miragen Therapeutics (MGEN) Now?
finance.yahoo.com - June 9 at 6:43 PM |
 | Miragen Therapeutics (MGEN) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 8 at 10:23 AM |
| miRagen Therapeutics to Present MRG-106 Phase 1 Clinical Trial Data at the International Conference on Malignant Lymphoma
finance.yahoo.com - June 8 at 10:23 AM |
| miRagen Therapeutics Presents New Data from Phase 1 Clinical Trial Evaluating MRG-106 in Subjects with Mycosis Fungoides
finance.yahoo.com - June 5 at 9:21 AM |
| Miragen Therapeutics, Inc. (MGEN) Upgraded at Zacks Investment Research
www.americanbankingnews.com - June 3 at 7:18 AM |
| Miragen Therapeutics, Inc. (MGEN) Earns Outperform Rating from Analysts at Cowen and Company
www.americanbankingnews.com - June 1 at 10:00 AM |
| miRagen Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - June 1 at 9:25 AM |
| Miragen Therapeutics (MGEN) Presents At UBS Global Healthcare Conference 2017 - Slideshow
seekingalpha.com - May 24 at 10:44 AM |
| miRagen Therapeutics Receives EU Orphan Medicinal Product Designation for MRG-106 for the Treatment of Cutaneous T-cell Lymphoma
finance.yahoo.com - May 24 at 10:44 AM |
| miRagen Therapeutics to Present New Clinical Trial Data for MRG-106, an Oligonucleotide Therapeutic Targeting microRNA-155, at the American Society of Clinical Oncology Annual Meeting
finance.yahoo.com - May 17 at 6:29 PM |
| Miragen Therapeutics, Inc. (MGEN) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 16 at 7:36 AM |
| Q2 2017 Earnings Forecast for Miragen Therapeutics, Inc. (MGEN) Issued By Wedbush
www.americanbankingnews.com - May 15 at 7:46 AM |
| Miragen Therapeutics, Inc. (MGEN) Forecasted to Earn Q1 2018 Earnings of ($0.34) Per Share
www.americanbankingnews.com - May 12 at 4:08 PM |
| Miragen Therapeutics, Inc. (MGEN) Posts Quarterly Earnings Results
www.americanbankingnews.com - May 11 at 7:18 PM |
| Miragen Therapeutics' (MGEN) Outperform Rating Reiterated at Wedbush
www.americanbankingnews.com - May 11 at 5:24 PM |
| miRagen Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - May 10 at 6:37 PM |
| Servier and miRagen extend collaboration for the research, development and commercialization of microRNA-targeting therapeutics
finance.yahoo.com - May 3 at 8:11 PM |
| miRagen Therapeutics to Host Conference Call Discussing First Quarter 2017 Corporate Update and Financial Results
finance.yahoo.com - May 2 at 4:39 PM |
 | miRagen Therapeutics (MGEN) Presents Interim Results from MRG-201 Phase 1 Clinical Trial
www.streetinsider.com - April 27 at 7:05 PM |
| miRagen Therapeutics Presents Interim Results from MRG-201 Phase 1 Clinical Trial Demonstrating Pharmacodynamic Activity in Human Skin Incisions
finance.yahoo.com - April 27 at 7:05 PM |
| miRagen Therapeutics to Participate in Two Investor Conferences in May
finance.yahoo.com - April 26 at 6:47 PM |
| Brokerages Expect Miragen Therapeutics, Inc. (MGEN) to Announce ($0.24) EPS
www.americanbankingnews.com - April 26 at 9:30 AM |
| miRagen Therapeutics to Present MRG-201 Data at the Society for Investigative Dermatology Annual Meeting
finance.yahoo.com - April 20 at 10:06 AM |
 | 4:15 pm Miragen Therapeutics reported recent clinical and financial highlights along with anticipated milestones for 2017
us.rd.yahoo.com - April 4 at 3:51 AM |
| Analysts Expect Miragen Therapeutics, Inc. (MGEN) to Post ($0.23) Earnings Per Share
www.americanbankingnews.com - April 3 at 11:37 PM |
| Miragen Therapeutics, Inc. (MGEN) Rating Reiterated by Wedbush
www.americanbankingnews.com - April 3 at 2:34 PM |
| miRagen Therapeutics Provides Corporate Update
finance.yahoo.com - March 31 at 6:38 PM |
| MIRAGEN THERAPEUTICS, INC. Files SEC form 8-K/A, Financial Statements and Exhibits
biz.yahoo.com - March 31 at 6:38 PM |
| miRagen Therapeutics Receives Orphan-Drug Designation for MRG-106 for the Treatment of Mycosis Fungoides
finance.yahoo.com - March 31 at 9:39 AM |
| 7:04 am Miragen Therapeutics announces that the FDA has granted orphan-drug designation to miRagen's product candidate, MRG-106, for the treatment of mycosis fungoides
finance.yahoo.com - March 31 at 9:39 AM |
| MIRAGEN THERAPEUTICS, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Change in Directors or
biz.yahoo.com - March 30 at 6:49 PM |
| miRagen Therapeutics to Present at the Needham and Company 16th Annual Healthcare Conference
finance.yahoo.com - March 28 at 10:28 AM |
| Wedbush Initiates Coverage on Miragen Therapeutics, Inc. (MGEN)
www.americanbankingnews.com - March 26 at 11:49 AM |
| MIRAGEN THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 24 at 6:33 PM |
| Kyle Lefkoff Sells 15,000 Shares of Miragen Therapeutics, Inc. (MGEN) Stock
www.americanbankingnews.com - March 8 at 10:04 PM |
| Miragen Therapeutics (MGEN) Presents At Cowen and Company 37th Annual Health Care Conference
seekingalpha.com - March 8 at 7:17 PM |
| miRagen Therapeutics to Participate in Two Investor Conferences in March
finance.yahoo.com - February 28 at 10:05 AM |
| Coverage initiated on Miragen Therapeutics by Wedbush
finance.yahoo.com - February 21 at 6:22 PM |
| Why miRagen Therapeutics Shares Could See 60% Upside By 2018
finance.yahoo.com - February 21 at 6:22 PM |
| MIRAGEN THERAPEUTICS, INC. Financials
finance.yahoo.com - February 17 at 5:23 PM |
Signal Genetics (MGEN) Chart for Tuesday, July, 25, 2017
